Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The cost of vision loss in Canada. 2. Results.
Cruess AF, Gordon KD, Bellan L, Mitchell S, Pezzullo ML. Cruess AF, et al. Can J Ophthalmol. 2011 Aug;46(4):315-8. doi: 10.1016/j.jcjo.2011.06.006. Epub 2011 Jul 7. Can J Ophthalmol. 2011. PMID: 21816249
Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.
Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, Greve M, Kozousek V, Lam WC, Maberley DAL. Hooper P, et al. Among authors: cruess a. Can J Ophthalmol. 2017 Nov;52 Suppl 1:S45-S74. doi: 10.1016/j.jcjo.2017.09.027. Can J Ophthalmol. 2017. PMID: 29074014 No abstract available.
Contemporary management of diabetic retinopathy in Canada: from guidelines to algorithm guidance.
Hooper P, Boucher MC, Colleaux K, Cruess A, Greve M, Lam WC, Shortt S, Tourville E. Hooper P, et al. Among authors: cruess a. Ophthalmologica. 2014;231(1):2-15. doi: 10.1159/000354548. Epub 2013 Nov 12. Ophthalmologica. 2014. PMID: 24246998
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy - executive summary.
Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee, Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, Greve M, Kozousek V, Lam WC, Maberley DA. Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee, et al. Among authors: cruess a. Can J Ophthalmol. 2012 Apr;47(2):91-6. doi: 10.1016/j.jcjo.2012.01.022. Can J Ophthalmol. 2012. PMID: 22560411 No abstract available.
Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.
Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, Greve M, Kozousek V, Lam WC, Maberley DA. Hooper P, et al. Among authors: cruess a. Can J Ophthalmol. 2012 Apr;47(2 Suppl):S1-30, S31-54. doi: 10.1016/j.jcjo.2011.12.025. Can J Ophthalmol. 2012. PMID: 22632804 English, French. No abstract available.
Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation.
Hodge W, Brown A, Kymes S, Cruess A, Blackhouse G, Hopkins R, McGahan L, Sharma S, Pan I, Blair J, Vollman D, Morrison A. Hodge W, et al. Among authors: cruess a. Can J Ophthalmol. 2010 Jun;45(3):223-30. doi: 10.3129/i10-047. Can J Ophthalmol. 2010. PMID: 20628420 Review.
The treatment of wet AMD in Canada: access to therapy (policy review).
Cruess A, Maberley D, Wong D, Chen J. Cruess A, et al. Can J Ophthalmol. 2009 Oct;44(5):548-56. doi: 10.3129/i09-140. Can J Ophthalmol. 2009. PMID: 19789590 Review.
Burden of illness of neovascular age-related macular degeneration in Canada.
Cruess A, Zlateva G, Xu X, Rochon S. Cruess A, et al. Can J Ophthalmol. 2007 Dec;42(6):836-43. doi: 10.3129/i07-153. Can J Ophthalmol. 2007. PMID: 18026200
Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammation.
Lafreniere JD, Toguri JT, Gupta RR, Samad A, O'Brien DM, Dickinson J, Cruess A, Kelly MEM, Seamone ME. Lafreniere JD, et al. Among authors: cruess a. Clin Exp Ophthalmol. 2019 Jul;47(5):638-645. doi: 10.1111/ceo.13453. Epub 2019 Jan 2. Clin Exp Ophthalmol. 2019. PMID: 30485637
Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
Berger A, Sheidow T, Cruess AF, Arbour JD, Courseau AS, de Takacsy F. Berger A, et al. Among authors: cruess af. Can J Ophthalmol. 2015 Jun;50(3):209-16. doi: 10.1016/j.jcjo.2014.12.014. Can J Ophthalmol. 2015. PMID: 26040221 Clinical Trial.
51 results
Jump to page
Feedback